Learn more about WIPO Re:Search members by viewing their detailed profiles.
WIPO Re:Search Resource Platform terms and conditions of use
Re:Search Institution Members
Export data
Choose one option to export the data.
PPT
153 Results for Members
Members
Aberystwyth University, located in Aberystwyth, Wales, was established in 1872. Its Institute of Biological,...
Founded in 2009, the Brazilian Biosciences National Laboratory (LNBio) is dedicated to cutting-edge...
At the Center for Infectious Disease Research (CIDR), scientists employ an arsenal of cutting-edge...
Case Western Reserve University (CWRU) is home to researchers performing malaria and schistosomiasis vaccine...
Health sciences is a core focus of research at Emory University; scientists within the university conduct both...
Researchers at GWU's Department of Microbiology, Immunology, and Tropical Medicine (MITM) conduct innovative,...
167 Results for Collaborations
Collaborations
Dr. Qvit was working with Dr. Mochly-Rosen to develop peptides that inhibit Leishmania-activated C kinase receptor homologue (LACK). Previous studies had shown that Leishmania LACK knockouts were nonviable, and parasites that expressed low levels of LACK were unable to infect immunocompromised mice. Dr. Qvit’s peptides had shown promise in in vitro assays, and he was interested in testing his peptides in vivo. BVGH connected Dr. Qvit with Dr. Siqueira-Neto at UCSD, who tested the peptides in his in vitro assays before he planned to test them in vivo. The compounds did not show activity in Dr. Siqueira-Neto’s in vitro assays, and he provided recommendations to Dr. Qvit for improving permeability before pursuing further testing.
The assays for screening compounds against Taenia crassiceps and T. solium, the causative agents of neurocysticercosis, are laborious and time-intensive. Drs. Nash and Mahanty at the NIH were interested in screening compounds that had already been pre-screened against schistosomiasis, in an effort to capitalize on the homology between the parasites that cause neurocysticercosis and schistosomiasis. BVGH connected the NIH investigators with Dr. Caffrey, who had identified compounds with promising activity against Schistosoma from a screen of cathepsin protease inhibitors. Dr. Caffrey shared these inhibitors with Drs. Nash and Mahanty, who screened them against T. crassiceps in vitro using biochemical assays for evidence of damage to parasites.
Olfat Hammam is a pathologist working at the Theodor Bilharz Research Institute (TBRI), Giza, Egypt, specialized in schistosomiasis. The objective of her yearlong sabbatical at Standford University, Palo Alto, California, was to conduct a research on the various mechanisms responsible for the association between urogenital schistomiasis and bladder cancer, and make a comparison in squamous cell carcinomas of the bladder in Europe, USA and Egypt, in order to better understand the links between Schistomiasis and these cancers. Working with Michael Hsieh, she learned up-to-date techniques in schistosomiasis research and animal modeling. Olfat Hammam contributed her pathology experience to the Stanford University by training laboratory members in immunohistochemistry and immunofluorescence methods.
Michael Hsieh is a urologist whose research interests include the roles of inflammation in defense against pathogens and carcinogenesis; mouse models of urogenital schistosomiasis; characterization of parasite-derived, host modulatory proteins as potential biomarkers of morbidity; and therapeutic exploitation of parasite-derived, host modulatory proteins for various diseases. He also hosts scientists interested in receiving training in his areas of expertise.
Accurate diagnosis of malaria and other parasitic diseases is challenging in field settings. Expensive, non-transportable equipment is usually required, significantly limiting timely diagnoses. In an effort to address this, Dr. Prakash developed the Foldscope, a lightweight, durable, inexpensive microscope made out of paper. The Foldscope provides sufficient magnification to diagnose several parasitic diseases including Malaria, HAT, leishmaniasis, and Schistosomiasis. Dr. Oyibo leads the ANDI Center of Excellence for Malaria Diagnosis at the University of Lagos, and hosted Dr. Prakash and his colleagues in Nigeria, providing plasma and whole blood samples from Plasmodium-infected individuals to test the Foldscope’s efficacy for Malaria diagnosis. While in Nigeria, the Stanford investigators also conducted training workshops on the Foldscope, and received input from infectious disease pathologists to further inform development of the technology. Plasma and whole blood samples to test the efficacy of a point-of-care microscopy diagnostic tool; hosting of Stanford researchers at University of Lagos for research and training; expertise sharing and feedback from infectious disease pathologists at the University of Lagos regarding Foldscope development.
Dr. Keiser is the Head of the Helminth Drug Development Unit at Swiss TPH. Dr. Keiser’s research is focused on drug discovery for helminth infections, and she evaluates compounds using both in vitro and in vivo assays. BVGH connected Dr. Keiser with Dr. Quinn, Director of the Eskitis Institute, who facilitated the sharing of a targeted selection of Nature Bank isolates for Dr. Keiser to screen against Schistosoma and Ancylostoma (hookworm).
Dr. Chen developed a PCR assay to identify resistance-causing mutations in Plasmodium parasite genes. Dr. Oyibo was interested in identifying specific mutations in Plasmodium parasites known to cause drug resistance in Nigerian patients, information that could potentially inform antimalarial treatment policy. With funding from NIPD, a graduate student from Dr. Oyibo’s laboratory spent two months at NIPD training on the PCR assay with samples collected from malaria patients in Nigeria. Using Dr. Chen’s assay, the student screened the samples for P. falciparum mutations conferring resistance to drugs.
170 Results for Assets
Assets
Professor Karl Hoffmann's laboratory has infrastructure to perform high-throughput, high content, whole organism screening assays for schistosomes and liver flukes. It can also perform vaccine / drug experiments in murine models of schistosomiasis. Aberystwyth University is committed to collaborations that facilitate neglected tropical disease basic and translational research opportunities.
Professor Karl Hoffmann’s laboratory has well-supported infrastructure in next generation sequencing, high performance computing, phenomics, biosafety level 2 laboratories for parasitological work (helminths) and small animal husbandry. Aberystwyth University is committed to collaborations that facilitate neglected tropical disease basic and translational research opportunities.
Mission: To be a prepared and fully functional cGMP manufacturing facility at all times in order to aid Army researchers in the development of vaccines for the war fighter. To achieve the mission of being ready and fully trained, the WRAIR PBF must continually develop and maintain projects and working relationships with other government entities (NIH, USAID, etc.) through Interagency Agreements and with universities and commercial companies and other private organizations through Cooperative Research and Development Agreements (CRADAs). Capabilities: Serving various clients and principal investigators, the WRAIR PBF can provide Phase1 and Phase 2 cGMP bacterial and viral vaccine constructs/production as follows: 1) Live, attenuated, killed or purified protein based vaccines; 2) Master and production seed/cell banking; 3) Fermentation (to 300 liters); 4) Protein purification; 5) Viral purification; 6) Aseptic filling of final vaccine material (validated to 2000 vials); 7) Lyophilization of final or bulk material; 8) Various types of vaccine product testing; 9) Specialized viral testing; 10) Stability program administration and testing for manufactured products. Major Accomplishments: 1)19 years of continual GMP manufacturing; 2) Worked with over 50 different clients/organizations; 3) Four products initiated at the PBF reaching licensure; 4) Pristine record of aseptic filling validation; 5)Type V Facility Master File filed and maintained at the FDA; 6) Excellent record of flexible and supportive service and interactions with clients; 7) Continual implementation of Validation Master Plan Fully developed GMP documentation system.
The technique called - codon harmonization - that combines bioinformatics, protein chemistry and genetic engineering to produce novel re-coded gene sequences for expressing recombinant antigens. Codon harmonization addresses several problems inherent to expressing proteins in heterologous hosts such as protein folding and insolubility. Such problems may be due to incorrect modulation of localized translations rates in the heterologous expression host. Codon harmonization engineers recombinant genes with synonymous codons so that codon usage frequencies match those found in the native host for expression in the heterologous host. Particular attention is focused on regions coded by low abundance t-RNA isoacceptor molecules which are predictive of interdomain, nonstructural regions within the protein. WRAIR has applied this technique to several malaria parasite genes including Pf MSP1-42 3D7, Pf MSP1-42 FVO, Pf MSP1-42 CAMP-FUP, Pf LSA1 and PfCelTOS, and has several patent applications related to this technique.
The Chemical Information System (CIS) is a research and management tool developed by the Department of Chemical Information (formerly the Chemical Handling and Data Analysis Branch). CIS use and function has evolved from a relatively simple inventory system to a powerful, integrated, Cheminformatics research and management tool. In recognition of the CIS's complexity and uniqueness, the United States Patent Office has granted Patent Number 6,654,736.
WRAIR has designed a one-step dengue RT-PCR: universal and serotype specific diagnostic kit. It is a fluorogenic detection system which demonstrated that universal dengue RT-PCR is capable of detecting all 4 dengue serotypes with excellent linearity. It was also confirmed that dengue type specific RT-PCR can specifically detect its corresponding serotype with little or no cross reactivity toward other serotypes.